Does this statin make you more likely to get diabetes after a kidney transplant?
#2667 The effect of pravastatin on insulin resistance in kidney transplant recipients. A randomized, placebo-controlled cross over trial
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Surprising Findings
Pravastatin showed no negative effect on insulin sensitivity despite strong prior evidence that other statins increase diabetes risk.
Most statins are linked to modestly higher diabetes rates — especially in insulin-resistant people — so finding zero effect in a high-risk group like transplant recipients contradicts the general narrative.
Practical Takeaways
Kidney transplant patients without diabetes who need a statin for heart health may consider pravastatin 40 mg/day as a lower-risk option for blood sugar.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Surprising Findings
Pravastatin showed no negative effect on insulin sensitivity despite strong prior evidence that other statins increase diabetes risk.
Most statins are linked to modestly higher diabetes rates — especially in insulin-resistant people — so finding zero effect in a high-risk group like transplant recipients contradicts the general narrative.
Practical Takeaways
Kidney transplant patients without diabetes who need a statin for heart health may consider pravastatin 40 mg/day as a lower-risk option for blood sugar.
Publication
Journal
Nephrology Dialysis Transplantation
Year
2025
Authors
Mai-Britt Skadborg, Henrik Birn, Niels Moeller, Niels Jessen, Lara Aygen Ozbay
Related Content
Claims (6)
HMG-CoA reductase inhibition with statins modestly increases the risk of developing type 2 diabetes, particularly in individuals with pre-existing insulin resistance.
Taking pravastatin for 12 weeks didn't make the body better or worse at using insulin to control blood sugar in people who had a kidney transplant and don't have diabetes.
Taking pravastatin for 3 months didn't raise or lower average blood sugar or long-term glucose control in kidney transplant patients without diabetes.
After drinking a sugary solution, pravastatin didn't make blood sugar rise more or less than a placebo in kidney transplant patients without diabetes.
Taking pravastatin for 3 months didn't harm the transplanted kidney's ability to work in patients without diabetes.